Key clinical point: In heavily pretreated pediatric patients with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma, venetoclax plus navitoclax with chemotherapy was well tolerated with promising responses.

Major finding: Complete responses, CRs with incomplete marrow recovery, and CRs without platelet recovery (CRp) combined occurred in 62% of B-ALL patients (8/13), 33% of T-cell acute lymphoblastic leukemia patients (1/3) and in 50% of lymphoblastic lymphoma patients (1/2).

Study details: The study included 18 pediatric patients with heavily pretreated relapsed or refractory acute lymphoblastic lymphoma or lymphoblastic lymphoma. Twelve were in the dose-escalation cohort and 6 in the safety-expansion cohort.

Disclosures: Dr. Rubnitz disclosed research funding from AbbVie.